Literature DB >> 6330381

Local recurrence after nephrectomy for primary renal cancer: computerized tomography recognition.

R A Parienty, F Richard, J Pradel, G Vallancien.   

Abstract

We diagnosed by computerized tomography 15 local recurrences in 88 patients who had undergone nephrectomy for renal cancer, with no false positives and 1 false negative. This over-all low rate (17 per cent) probably is owing to the fact that computerized tomography scans were done in patients in good clinical condition. Local recurrence was noted in 3 of 59 asymptomatic patients and in 12 of 19 patients with local symptoms. No recurrence was noted in 10 patients with general symptoms. Thus, 20 per cent of local recurrences were asymptomatic and 80 per cent presented with local symptoms. High local recurrence rates were found in cases of transitional cell carcinoma with whole wall involvement or extension to adjacent tissues (4 of 8 patients, 50 per cent), clear cell adenocarcinoma with lymph node involvement (3 of 7 patients, 43 per cent) and partial nephrectomy (3 of 6 patients, 50 per cent). Therefore, we consider such patients to be at high risk. Our study demonstrates that computerized tomography enables earlier, accurate diagnosis of smaller local recurrence in asymptomatic patients and provides a sensitive, reliable, noninvasive, repetitive method of evaluation of clinical treatment trials. Routine followup should be reserved for high risk patients.

Entities:  

Mesh:

Year:  1984        PMID: 6330381     DOI: 10.1016/s0022-5347(17)49578-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

Review 1.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

Review 2.  The role of lymphadenectomy in renal cell carcinoma.

Authors:  Hyung L Kim; John S Lam; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.